Gilead Sciences
Update in progressGILD (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - General
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines to address unmet medical needs worldwide. It markets HIV therapies (Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, Yeztugo) and hepatitis/viral treatments (Epclusa, Livdelzi, Vemlidy). It also offers Tecartus and Yescarta CAR-T therapies, Trodelvy, AmBisome, and Veklury for COVID-19. Headquartered in Foster City, CA, it pursues numerous collaborations.
Company score
- Sentiment
- 1.82
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.16
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 1.70
- Governance
- -0.35
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.48
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 1.15
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Daniel Patrick O'Day
- Founded1987
- Employees17,000
- Websitewww.gilead.com
Identifiers
- ISINUS3755581036
- FIGIBBG000CKGBP2
- LEI549300WTZWR07K8MNV44
- CUSIP375558103
- CIK0000882095